trending Market Intelligence /marketintelligence/en/news-insights/trending/ZIvLqv6WJQH0wMKxWLfPvQ2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Getinge to acquire Applikon Biotechnology for 840M Swedish kronor


M&A rebound sparks optimism for near-term deal activity


Needham & Company is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection


Banking Essentials Newsletter - February Edition


Message in a (Word)Cloud

Getinge to acquire Applikon Biotechnology for 840M Swedish kronor

Getinge AB agreed to acquire privately held Dutch company Applikon Biotechnology BV for 840 million Swedish kronor in cash.

Under the agreement, the Swedish healthcare company will purchase all of Applikon Biotechnology's outstanding common shares. Getinge could pay up to 630 million kronor in additional earnout fees in 2021-2022 upon the achievement of certain earnings performance in 2020-2021.

Getinge said it does not expect any material impact on its 2020 earnings.

The acquisition, which will be financed through debt, is expected to close during the first quarter of 2020.

Deutsche Bank is Getinge's exclusive financial adviser and NautaDutilh the legal adviser for the deal.

As of Dec. 18, US$1 was equivalent to 9.42 Swedish kronor.